Search company, investor...
SOPHiA Genetics company logo

SOPHiA Genetics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About SOPHiA Genetics

SOPHiA Genetics (NASDAQ:SOPH) is a health technology company. It focuses on data-driven medicine as the standard of care and for life sciences research. It develops a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets. It develops an advanced technology that analyzes and detects all types of genomic variants to help clinicians better diagnose and treat their patients. The company was founded in 2011 and is based in Saint Sulpice, Switzerland.

Headquarters Location

Rue du Centre 172

Saint Sulpice, 1025,


+41 21 694 10 60

Missing: SOPHiA Genetics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SOPHiA Genetics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing SOPHiA Genetics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned SOPHiA Genetics in 5 CB Insights research briefs, most recently on Dec 20, 2022.

Expert Collections containing SOPHiA Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SOPHiA Genetics is included in 11 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

10,627 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,623 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

10,347 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

SOPHiA Genetics Patents

SOPHiA Genetics has filed 21 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA sequencing
  • Genomics
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Bioinformatics, Genomics, DNA sequencing, Genetics


Application Date


Grant Date



Related Topics

Molecular biology, Bioinformatics, Genomics, DNA sequencing, Genetics



Latest SOPHiA Genetics News

SOPHiA GENETICS Joins CancerX to Help Accelerate Cancer Research

Jun 2, 2023

06/02/2023 | 09:32am EDT Message : *Required fields As a leader in data-driven medicine, SOPHiA GENETICS lends its expertise to support White House Cancer Moonshot BOSTON and LAUSANNE, Switzerland, June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced today at ASCO that it has joined as a founding member of CancerX , a new public-private partnership formed to rapidly accelerate the pace of cancer innovation in the United States. As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research. SOPHiA GENETICS offers its SOPHiA DDM™ Platform, powered by artificial intelligence and machine learning, to help advance the inaugural project, which looks to improve equity and reduce cost in cancer treatments. CancerX was announced by the White House in February 2023 as part of the reignited national Cancer Moonshot initiative. Co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), CancerX will unite stakeholders and innovators to unleash the power of innovation and create a future that is free of the burden of cancer. "As a leader in data-driven medicine, SOPHiA GENETICS is eager to join forces with CancerX and its partners that will lend their expertise towards expediting cancer research and innovation in the U.S.," said Kevin Puylaert, Vice President, Business Development & Marketing for SOPHiA GENETICS. "CancerX founding member Memorial Sloan Kettering Cancer Center  (MSK) is among the 750+ institutions within our global data-sharing network. We look forward to leveraging the collective intelligence that our platform creates to help progress cancer research as we embark on our work with CancerX." In early 2022, President Biden reignited the  Cancer Moonshot , setting new national goals to cut the death rate from cancer by at least 50 percent over the next 25 years and improve the experience of people and their families living with and surviving cancer. In February 2023, the White House announced CancerX, which strives to unite a diverse and inclusive community of stakeholders and harness their collective superpowers to rapidly pioneer and equitably deploy innovative solutions that can prevent and cure cancer. "Beating cancer demands bold innovation and deliberate collaboration. CancerX is creating a dynamic ecosystem where ideas can flourish, expertise and resources can be shared, and innovative solutions can be rapidly developed and equitably deployed in the fight against cancer. As a co-host, we take immense pride in the diverse and inclusive community of pioneers coming together as members, all driven by a shared commitment to advancing the goals of the Cancer Moonshot. Together, we will advance the frontiers of cancer research and treatment through digital innovation, while striving to reduce the incidence and burden of cancer for all people." said Santosh Mohan, Vice President, Digital, Moffitt Cancer Center. While data analysis in the lab can be costly, siloed and time intensive, SOPHiA GENETICS' technology breaks down these barriers, facilitating information-sharing and streamlined data analysis. The SOPHiA DDM™ Platform will not only help bring CancerX partner data together but will accelerate research work to help facilitate breakthroughs. "Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with SOPHiA GENETICS to achieve the ambitious goals of CancerX," said Smit Patel, Associate Program Director at DiMe. "Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey." For more information on SOPHiA GENETICS, visit  SOPHiAGENETICS.COM , or connect on  Twitter ,  LinkedIn ,  Facebook , and  Instagram . About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit  SOPHiAGENETICS.COM , or connect on  Twitter ,  LinkedIn ,  Facebook , and  Instagram . Where others see data, we see answers. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact to obtain the appropriate product information for your country of residence. SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. View original content to download multimedia: SOURCE SOPHiA GENETICS

SOPHiA Genetics Frequently Asked Questions (FAQ)

  • When was SOPHiA Genetics founded?

    SOPHiA Genetics was founded in 2011.

  • Where is SOPHiA Genetics's headquarters?

    SOPHiA Genetics's headquarters is located at Rue du Centre 172, Saint Sulpice.

  • What is SOPHiA Genetics's latest funding round?

    SOPHiA Genetics's latest funding round is IPO.

  • How much did SOPHiA Genetics raise?

    SOPHiA Genetics raised a total of $250.82M.

  • Who are the investors of SOPHiA Genetics?

    Investors of SOPHiA Genetics include Swisscom Ventures, Alychlo, Endeavour Vision, Generation Investment Management, aMoon Fund and 15 more.

  • Who are SOPHiA Genetics's competitors?

    Competitors of SOPHiA Genetics include nference and 6 more.

Compare SOPHiA Genetics to Competitors

Owkin Logo

Owkin specializes in artificial intelligence technologies applied to clinical research and developing drugs and treatments for patients. It empowers researchers in hospitals, universities, and the biopharma industry to understand drug efficacy varies, improves the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company was founded in 2016 and is based in New York, New York.

ConcertAI Logo

ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.

Tempus Logo

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility. The company enables physicians to deliver personalized cancer care for patients through analytical and machine-learning platforms. It provides genomic sequencing services and molecular therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. It was formerly known as Tempus Consulting. The company was founded in 2015 and is based in Chicago, Illinois.

Innoplexus Logo

Innoplexus applies its proprietary tech stack in all stages of the drug development value chain via smart Data as a Service and Continuous Analytics as a Service solution. Generating insights from hundreds of Terabytes of structured and unstructured private and public data, Innoplexus helps organizations move towards continuous decision-making.

Atomwise Logo

Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.

Omixon Logo

Omixon is a global molecular diagnostics company that commercializes technologies for clinical and research laboratories. Omixon's flagship product, Holotype HLA, is an NGS-based HLA genotyping product that delivers high-resolution HLA genotyping. Omixon's research software, HLA Explore, analyzes data from any sequencing technology and determines HLA genotypes from whole exome/genome sequencing experiments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.